anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVE: Heart rhythm disorder is one of the most common problems after coronary artery bypass graft surgery. Various factors, such as the history of sleep apnoea before the operation, may aggravate the occurrence of this disorder. The present study was conducted to determine the relationship between sleep apnoea before surgery and heart rhythm disorder after surgery in patients undergoing coronary Artery Bypass Grafting in 2019.
METHODS: This analytical cross-sectional study was conducted on 192 patients who were selected by sequential sampling. The research tool included demographic information, a checklist of heart rhythm disorders, and the Berlin sleep apnoea questionnaire. Descriptive statistics and the Chi-square test, Fisher's exact test, Mann-Whitney's U-test, and logistic regression were used to analyze the data.
RESULTS: A total of 71.35% of the samples were male, and the mean age of the participants was 57.8 ± 7.5 years. Also, 46.0% of the samples had sleep pane and 21.35% had rhythm disorder. The most frequent heart rhythm disorder in patients with obstructive sleep apnoea was atrial fibrillation. There was a significant relationship between the occurrence of rhythm disorder and a history of smoking (P = 0.021), and the regression model showed that a history of smoking is the only variable related to the occurrence of rhythm disorder after coronary Artery Bypass Grafting (P = 0.005, CI 95%: 6.566-1.386, OR = 3.017).
CONCLUSIONS: The results showed that there is no statistically significant relationship between sleep apnea and rhythm disorder after coronary artery bypass surgery.
This study uses a new testing design to evaluate pain reduction from a pain-relieving cream. Sequences of heat stimuli will be applied to the participants arms and participants will be asked to judge the intensity of the temperatures they perceive. There are two study sessions. Session 1 involves eligibility screening and baseline sensory testing with and without the analgesic (pain-relieving) cream. Session 2 involves more sensory testing with the analgesic cream. The study population is 40 healthy volunteers aged 18 to 50.
Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided is a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.
Placebo + PCA group (G2): patients undergoing knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve blockade (femoral nerve and obturator nerve). With conventional analgesia and with the PCA apparatus.
PURPOSE OF REVIEW: This review summarizes the literature about the transition from psoriasis to psoriatic arthritis (PsA), focusing on musculoskeletal ultrasound (MSUS) for detecting subclinical inflammation and its role in diagnosis and triage of high-risk patients.
RECENT FINDINGS: MSUS effectively detects subclinical musculoskeletal inflammation in patients with psoriasis; however, some of these lesions are non-specific and can be found in healthy individuals. Preliminary evidence suggest that subclinical sonographic findings may predict progression to PsA in psoriasis patients. MSUS can also improve referrals' accuracy and its integration in the PsA classification criteria may improve early PsA detection. MSUS is a valuable tool for detecting subclinical abnormalities in psoriasis patients, which indicate an increased likelihood of progressing to PsA. Its integration into referral protocols and clinical use could improve PsA diagnosis. We propose an MSUS-inclusive algorithm for PsA referrals and triage, which requires validation. The potential of early intervention in reducing PsA progression in psoriasis patients with subclinical inflammation remains to be established.
PURPOSE:To titled inhibitor, containing a specific peptide as an active constituent, and capable of acting effectively in the injection site by adding to a pharmaceutical for injection. CONSTITUTION:An inhibitor for the decomposition of calcitonin containing a peptide, e.g. calcitonin fragment (11-32), having a peptide chain at the 11-12, 18-19 or 24-25 positions in the fragment having the same amino acid sequence as in the calcitonin obtained easily in synthesizing the calcitonin, e.g. ''Elcitonin '' derived from a rabbit or natural clacitonin derived from a salmon or pig, as an active constituent. The calcitonin is a peptide hormone consisting of 32 amino acids having the activity of reducing the blood serumal calcium. The use of the inhibitor in an amount of 5 times or more, preferably 10 times or more, based on the calcitonin inhibits the decomposition of the calcitonin well in the injection site. Thus, the resultant inhibitor is used as an additive in a pharmaceutical for injecting the calcitonin.
The active control group will receive oral formulation of Naproxen Sodium 550mg (Tab. Synflex) twice a day, after meals for 24 hours.
A synthetic resin matrix system for the delayed and extended duration delivery of drugs to humans and animals is disclosed consisting of a polymer, such as poly(2-hydroxyethylmethacrylate), referred to as PHEMA, an organic solvent, such as polyethylene glycol (PEG), and a hydrogen binding plasticizer, such as dimethylsulfoxide (DMSO). The plasticizer regulates the set-up time of the synthetic resin so that the more plasticizer present, the shorter the set-up time. The plasticizer also has a direct shortening effect upon the cure time and also profoundly influences many of the physical characteristics of the resultant synthetic resin matrix system. A variety of drugs can be embodied in the fabricated matrix system and administered to the patient (or animal) by different modes of application, including but not limited to oral, topical, rectal, subcutaneous implant, or organ-specific implant such as in the conjunctival sac of the eye. These formulations and procedures can also be utilized in the storage and extended-duration delivery of agricultural products, particularly herbicides, insecticides, and nutritional supplements. By manipulating the relative concentrations of the components of the matrix system and the particle size of the embedded active agent, it is possible to control the release dynamics of the active embodied agent from the matrix and thus provide unique controlled delayed and extended delivery of the active agent.
The NICHD interview protocol was designed to aid forensic interviewers in adhering to best standards of practice when interviewing children. Field studies evaluating its use have demonstrated improvements in both interviewer behavior, and the amount and quality of information obtained from children, compared to interviews conducted prior to its implementation in test sites. Because field studies were conducted in forensic settings, however, it has not been possible to evaluate the protocol's effect on the accuracy of information reported by children. This present study therefore aims to evaluate the accuracy of information obtained using the NICHD interview protocol in an analog study. In addition the study is designed to explore children's willingness to provide details of a suggested, non-experienced event, and the effectiveness of including a human figure drawing as an auxiliary technique for eliciting further information. Furthermore, we will explore the importance of the pre-substantive/rapport-building phase of interviews, and the impact this has on children's reports of experienced and suggested events. Finally, we will explore the effectiveness of the interview protocol with children when a long delay has occurred between the event and the interview.

Children will take part, individually, in a staged event at their school, and approximately six weeks later, be interviewed at the university about what they experienced. In addition, children will be asked to talk about a suggested fictitious event (one that has not happened). The order of the interviews will be counter-balanced across children and rapport-building conditions. Some children will be interviewed with an open-ended script that includes practice in episodic memory, some with a script made up of direct questions, including a practice in episodic memory, and some with one that uses open-ended questions but does not provide practice in talking about an event from episodic memory. Approximately one year later children will be interviewed again, so that we can examine children's reports in protocol interviews over a long delay. Children's reports will be analyzed for both overall amount and accuracy of information reported, as well as in response to the different cues and props given in the course of the interview. It is not anticipated that the study will pose any risks to the children involved, and we expect that both the staged event and the interviews will be enjoyable and stimulating. We expect that the results of the study will provide further support for the use of NICHD interview as a safe and effective means of interviewing children about past experiences. In addition to general information on children's eyewitness capabilities, the study is expected to supplement field studies by contributing knowledge about the accuracy of children's memory using the NICHD interview protocol.
Since its development in 1943, lidocaine has been one of the most commonly used local anesthesia agents for surgical procedures. Lidocaine alters neuronal signal transmission by prolonging the inactivation of fast voltage-gated sodium channels in the cell membrane of neurons, which are responsible for action potential propagation. Recently, it has attracted attention due to emerging evidence suggesting its potential antitumor properties, particularly in the in vitro setting. Further, local administration of lidocaine around the tumor immediately prior to surgical removal has been shown to improve overall survival in breast cancer patients. However, the exact mechanisms driving these antitumor effects remain largely unclear. In this article, we will review the existing literature on the mechanism of lidocaine as a local anesthetic, its effects on the cancer cells and the tumor microenvironment, involved pathways, and cancer progression. Additionally, we will explore recent reports highlighting its impact on clinical outcomes in cancer patients. Taken together, there remains significant ambiguity surrounding lidocaine's functions and roles in cancer biology, particularly in perioperative setting.
<P>PROBLEM TO BE SOLVED: To obtain an estrogen receptor damage inhibitor characterized by containing an extract of a mushroom belonging to the genus Ganodermataceae.  <P>SOLUTION: This estrogen receptor damage inhibitor is characterized by containing the extract of the mushroom belonging to the genus Ganodermataceae. The extract of the mushroom belonging to the genus Ganodermataceae exhibits an excellent estrogen receptor damage-inhibiting effect. The estrogen receptor damage inhibitor containing the extract of the mushroom belonging to the genus Ganodermataceae is safe and exhibits an excellent ageing-preventing effect. A cosmetic, quasi-medicine, medicine or food containing the extract of the mushroom belonging to the genus Ganodermataceae is also safe and exhibits an excellent ageing-preventing effect.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention belongs to the field of medicines, and discloses a prescription for treating premature graying. The prescription is composed of the following raw materials by weight: 10 to 15 grams of prepared radix rehmanniae, 20 to 30 grams of walnut kernel, 10 to 15 grams of mulberry leaf, 5 to 10 grams of poria cocos, 20 to 30 grams of black sesame, and 10 to 20 grams of white sugar. The provided prescription has a simple formula, can provide nutrients for human body, and is capable of curing premature graying effectively and safely. In the prescription, prepared radix rehmanniae has the functions of nourishing yin, tonifying blood, boosting essence, and replenishing the marrow; walnut kernel has the functions of tonifying kidney, warming the lung, and moistening intestines; mulberry leaf has the functions of dispelling wind heat, clearing lung, moistening dryness, clearing liver, and improving the eyesight; poria cocos has the functions of invigorating the spleen and tranquilizing; and black sesame can be used as food and medicine and has the functions of tonifying kidney and liver, boosting essence and blood, and moistening the intestines. The prescription is very safe, can be used for a long term, is capable of treating premature graying, and can supply nutrients for human body at the same time to improve the immunity. The prescription is taken by the following steps: removing stalks from mulberry leaves, grinding the processed mulberry leaves into powder; frying black sesames, then grinding the boiled black sesames into powder; grinding walnut kernels into powder; evenly mixing the powders and white sugar, saving the mixture for later use; boiling prepared radix rehmanniae in water so as to obtain water decoction, evenly mixing the water decoction and the mixture together, and orally taking the prescription in the morning and evening under the assist of warm water.
EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
BACKGROUND: A carotid-cavernous fistula is an abnormal communication between the arteries and veins within the cavernous sinus. While conservative management may be prudent in low risk cases, many patients require intervention and endovascular embolization has evolved as the preferred method of treatment. Embolization can be performed via either the transarterial or transvenous approach. One major challenge of the transvenous approach is the complex and variable compartmentation of the cavernous sinus, which often requires the use of low profile microcatheters to navigate and reach the fistulous point. Fibered coils are also preferred when performing transvenous embolization of carotid-cavernous fistula, as they are of higher thrombogenicity and allow for faster occlusion of the fistula. However, most low profile (0.017-inch) microcatheters are not able to deploy fibered coils based on the manufacturer's instructions.
CASE PRESENTATION: We present two successful cases of off-label use of Medtronic Concerto fibered coils via a 0.017-inch microcatheter during transvenous embolization of carotid-cavernous fistula in a 60-year-old and an 80-year-old Chinese female, respectively.
CONCLUSION: Our case series highlight the possibility of deploying large diameter (up to 10 mm) Concerto fibered coils through a low profile (0.017-inch) microcatheter in an off-label manner for transvenous embolization of indirect carotid-cavernous fistula.
An 8-module internet-delivered cognitive behavioral therapy program. Participants receiving treatment will simultaneously use "Spelpaus" - a self-exclusion gambling service.
PURPOSE:To obtain a therapeutic agent for keloids having high improving effects on the keloids and high safety without causing any pain to a patient. CONSTITUTION:This therapeutic agent for keloids comprises a humectant cream or a humectant liquid containing a humectant ingredient and a film-forming type pack applied onto the humectant cream or humectant liquid. Saccharides, water-soluble polymers and polyhydric alcohols are cited as the humectant ingredient. Furthermore, although the film-forming type pack may be a usual one, it has preferably the flexibility from the viewpoint of adhesion to a lesion and is preferably dried as quickly as possible to form a film after application thereof to the lesion. The humectant cream or the humectant liquid is applied to a wound lesion and the pack is then applied thereto and dried. The peripheral part of the pack film is subsequently fixed to the skin and applied thereto.
Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
To evaluate the safety and tolerability of P2203. In Cohort 1, the first two subjects will be the sentinel subjects treated with staggered dosing. The 1st sentinel subject of Cohort 1 will be dosed at least 96 hours prior to the 2nd sentinel subject. The 2nd sentinel subject will receive P2203 when the Criteria for Dosing Suspension or Termination in a Given Dose Cohort is not met at least during the first 96 hours following administration of P2203 of the 1st sentinel subject. The remaining subject in Cohort 1 will receive P2203 when the Criteria for Dosing Suspension or Termination in a Given Dose Cohort is not met at least during the first 96 hours following administration of P2203 of the 2nd sentinel subject.
FIELD: confectionery industry. SUBSTANCE: method involves extruding mixture of sweeteners in melting zone at temperature of 130-120 C, in vacuumizing zone under reduced pressure and at temperature of 120-160 C and in cooling zone at temperature of 60-130 C; producing pellets and hard boiled candy. Method allows glassy melt cooling time to be reduced and aromatic and active substances to be introduced at lower temperatures. Products manufactured from glassy melt are readily processed. EFFECT: increased efficiency, wider range and improved quality of products manufactured from glassy melt. 19 cl, 2 dwg
Pyroptosis is a proinflammatory type of regulated cell death and has been involved in many pathological processes. Inhibition of pyroptosis is thought to be a promising strategy for the treatment of related diseases. Here, we performed a phenotypic screening against NLRP3-dependent pyroptosis and obtained the novel compound N77 after structure optimization. N77 showed a half-maximal effective concentration (EC50) of 0.070 ± 0.008 μM against cell pyroptosis induced by nigericin, and exhibited a remarkable ability to prevent NLRP3-dependent inflammasome activation and the release of IL-1β. Chemical proteomics revealed the biological target of N77 to be glutathione-S-transferase Mu 1 (GSTM1); our mechanism of action studies indicated that GSTM1 might act as a negative regulator of NLRP3 inflammasome activation by modulating the glutathionylation of caspase-1. In vivo, N77 substantially alleviated the inflammatory reaction in a pyroptosis-related acute keratitis model. Overall, we identified a novel pyroptosis inhibitor and revealed a new regulatory mechanism of pyroptosis. Our findings suggest an alternative potential therapeutic strategy for pyroptosis-related diseases.
Patients with known endometriosis based on prior surgical pathology or suspected endometriosis based on symptomatology who plan on undergoing diagnostic laparoscopy will be offered enrollment in the study. They will complete preoperative pain assessments with the tools outlined above. At the time of diagnostic laparoscopy, patients found to have endometriosis will be staged according to the American Society of Reproductive Medicine guidelines. Patients with Stage 4 or deeply infiltrating endometriosis will be excluded from the study. At that point, the patients will be randomized in the operating room to either laparoscopic excision of endometriosis or laparoscopic ablation with the argon beam coagulator. Patients will be stratified according to the presence or absence of the Levonorgestrel-Intrauterine Device.

Pain assessments will be performed immediately postoperatively in the recovery area. Pain assessments will again be performed at 4 weeks, 6 months and 12 months. We will use the VAS pain scale and validated questionnaires.
This is a phase I, randomised, double-blind , placebo controlled study to investigate the safety, tolerability, and PK of AX-158 in healthy male participants following single (Part A) and multiple (Part C) ascending doses including food effect (Part B).The study will be conducted in three parts (Part A, Part B and Part C). Part A will enrol 8 participants per cohort randomised (3 :1) to receive AX-158 (6 participants) or placebo (2 participants). Part A will follow a single ascending dose (SAD) design with all participants receiving one dose of AX-158 (or placebo) in the fasted state. Part B (Food Effect) will be conducted in 8 participants in a cross-over manner; each participant will receive AX-158 in the fed and fasted state. Part C will enrol 8 participants per cohort randomised to (3 :1) to receive AX-158 (6 participants) or placebo (2 participants). Part C will follow a multiple ascending dose (MAD) design with participants receiving AX-158 (or placebo) once daily for 10 consecutive days, in a fed or fasted state (depending on the outcome of the Part B (Food Effect).
Provided is a composition that comprises a supernatant of brown adipocytes or a purified product thereof and has a metabolism improving effect. Also provided is a method for preparing the aforesaid supernatant without using a liquid culture containing glucose at a high concentration. Also provided is a method for producing brown adipocytes using pluripotent stem cells, said method being useful for preparing a supernatant of brown adipocytes. In the present invention, a supernatant having a metabolism improving effect was successfully obtained from brown adipocytes. Also, this supernatant could be obtained without using a liquid culture containing glucose at a high concentration. In the present invention, moreover, brown adipocytes were successfully formed from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail, etc. The supernatant of brown adipocytes according to the present invention is expected as applicable to the development of therapeutic drugs for sugar metabolism-related diseases and cosmetics.